Research and Markets: The Value of the Pharmaceutical Market for Pain Relief Reached nearly $23 billion in 2004.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c19098) has announced the addition of Pain Therapeutics 2005:Market Dynamics and Outlook to their offering. Pain Therapeutics 2005: Market Dynamics and Outlook provides detailed analysis and information concerning the global market for pain therapeutics, R&D pipelines and company involvement in this field. About one and a half billion people suffer from moderate to severe chronic pain worldwide and approximately 50 million Americans suffer with pain. The value of the pharmaceutical market for pain relief reflects this seeming worldwide epidemic of pain, with the overall value reaching nearly $23 billion in 2004. In this new report, key pain management therapeutics such as Cox-II inhibitors, opioids Opioids One of the major classes of semi or fully synthetic psycho-active drugs that includes methadone. Mentioned in: Cancer Therapy, Palliative, Methadone opioid , triptans, anticonvulsants Anticonvulsants Drugs used to control seizures, such as in epilepsy. Mentioned in: Antipsychotic Drugs, Osteoporosis and traditional NSAIDs are discussed in terms of their past, present and future value and the role they are playing in the effective management of pain. The dynamics of this market have been altered greatly over the past year. The troubles surrounding the multi-billion dollar Cox-II class has created a void in the marketplace. Pain Therapeutics 2005 explains just what the Cox-II crisis means for the future of pain management and what kinds of opportunities their failure may present for other classes of pain management medications. Pain Therapeutics 2005 also analyzes the markets and provides forecasts for: --the fast-growing anticonvulsant anticonvulsant /an·ti·con·vul·sant/ (-kon-vul´sant) inhibiting convulsions, or an agent that does this. an·ti·con·vul·sant n. A drug that prevents or relieves convulsions. class --migraine therapies --traditional NSAIDs - and opioids. This report looks at the following key topics: Causes, Classifications and Global Impact of Pain Treating Pain: Drug Classes and Guidelines Post-Operative Pain Overview and Therapeutic Options Back Pain Overview and Therapeutic Options Neuropathic neuropathic /neu·ro·path·ic/ (-path´ik) pertaining to or characterized by neuropathy. neuropathic pertaining to disease of the nervous system. Pain Overview and Therapeutic Options Migraine Overview and Therapeutic Options Cancer Pain Overview and Therapeutic Options Arthritic Pain Overview and Therapeutic Options Fibromyalgia fibromyalgia Chronic syndrome that is characterized by musculoskeletal pain, often at multiple sites. The cause is unknown. A significant number of persons with fibromyalgia also have mental disorders, especially depression. Overview and Therapeutic Options Non-Pharmaceutical Pain Treatment NSAID NSAID: see nonsteroidal anti-inflammatory drug. Market Analysis Opioid opioid /opi·oid/ (o´pe-oid) 1. any synthetic narcotic that has opiate-like activities but is not derived from opium. 2. any of a group of naturally occurring peptides, e.g. Use and Market Trends Migraine Therapy Market Anticonvulsant Market Cox-II Inhibitors and the Future Promising Areas of Research Company Profiles: Abbott Laboratories Abbott Laboratories (NYSE: ABT) is a diversified pharmaceuticals and health care company. It has over 65,000 employees and operates in 130 countries. The corporate headquarters are in Abbott Park, Illinois, a neighborhood of North Chicago, Illinois. AlgoRx Pharmaceuticals Altea Therapeutics Ardent Pharmaceuticals AstraZeneca Cephalon Ceph´a`lon n. 1. (Zool.) The head. Elan Pharmaceuticals Endo Pharmacuticals EpiCept GlaxoSmithKline Indevus Pharmaceuticals Innovative Drug Delivery Systems Johnson & Johnson Metaphore Pharmaceuticals Nastech Pharmaceutical NeurogesX Novartis Pharmaceuticals Pain Therapeutics Pfizer Purdue Renovis SkyePharma For more information visit http://www.researchandmarkets.com/reports/c19098 |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion